We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+14.51%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$997M
AUM Growth
+$109M
Cap. Flow
+$118M
Cap. Flow %
11.83%
Top 10 Hldgs %
74.49%
Holding
41
New
11
Increased
8
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$37.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$24.2M
3
WVE icon
Wave Life Sciences
WVE
+$22M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
URGN icon
UroGen Pharma
URGN
+$20.2M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$16M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$10.3M
4
ONC
BeOne Medicines Ltd
ONC
+$8.18M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.62M

Sector Composition

Rank Sector Weight
1 Healthcare 93.61%
2 Miscellaneous 6.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
1
Assembly Biosciences
ASMB
$694M
$145M 14.51%
245,264
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.3B
$119M 11.96%
1,822,575
-285,025
-14% -$16M
KYNB
3
Kyntra Bio
KYNB
$32.5M
$92.5M 9.28%
80,097
-1,812
-2% -$2.39M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$682M
$90.8M 9.11%
7,027,386
– –
KURA icon
5
Kura Oncology
KURA
$1.13B
$70.6M 7.08%
3,766,852
– –
WVE icon
6
Wave Life Sciences
WVE
$993M
$58.5M 5.87%
1,459,072
+522,909
+56% +$22M
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
$49.8M 4.99%
3,049,312
+166,600
+6% +$2.67M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$45.5M 4.57%
4,764,447
-72,100
-1% -$777K
MGNX icon
9
MacroGenics
MGNX
$263M
$36.5M 3.66%
1,450,606
+309,812
+27% +$7.53M
RCUS icon
10
Arcus Biosciences
RCUS
$3.72B
$34.5M 3.46%
+2,236,387
New +$37.3M
CELG
11
CALL
DELISTED
Celgene Corp
CELG
$34.3M 3.44%
385,000
-490,000
-56% -$47M
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$23.4M 2.34%
1,056,348
-88,210
-8% -$1.73M
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$21.3M 2.14%
+1,240,470
New +$24.2M
URGN icon
14
UroGen Pharma
URGN
$2.13B
$20M 2.01%
+402,300
New +$20.2M
KYNB
15
CALL
Kyntra Bio
KYNB
$32.5M
$15M 1.51%
13,000
+1,584
+14% +$2.09M
IMDZ
16
DELISTED
Immune Design Corp.
IMDZ
$14.4M 1.45%
4,437,600
+875,000
+25% +$3.1M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$1.99B
$14.1M 1.42%
+172,952
New +$13.4M
AKBA icon
18
Akebia Therapeutics
AKBA
$243M
$13.6M 1.36%
+1,425,000
New +$19.9M
ACHN
19
DELISTED
Achillion Pharmaceuticals
ACHN
$13.6M 1.36%
3,668,307
+1,827,582
+99% +$5.98M
DOVA
20
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$11.7M 1.17%
+429,729
New +$12.9M
ATYR
21
aTyr Pharma
ATYR
$53M
$10.6M 1.06%
279,855
– –
DBVT
22
DBV Technologies
DBVT
$851M
$10.4M 1.04%
+45,000
New +$10.6M
IRWD icon
23
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$10.3M 1.03%
797,353
+200,353
+34% +$2.5M
PTGX icon
24
Protagonist Therapeutics
PTGX
$9.34B
$9.31M 0.93%
+1,083,567
New +$20.4M
SYBX
25
DELISTED
Synlogic
SYBX
$6.57M 0.66%
+46,667
New +$7.23M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2018 Portfolio in Review

As of Q1 2018, EcoR1 Capital held 41 positions worth $997M, up 12% from $888M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

EcoR1 Capital deployed $118M of net new capital in Q1 2018, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Arcus Biosciences: 2,236,387 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 84% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $16M trimmed.

  • EcoR1 Capital's largest Q1 2018 buy was Arcus Biosciences: 2,236,387 shares worth $34.5M.
  • EcoR1 Capital added most to Wave Life Sciences in Q1 2018, an estimated $22M increase.
  • EcoR1 Capital's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $16M.
  • EcoR1 Capital fully exited MyoKardia, Inc. Common Stock in Q1 2018, selling an estimated $32.8M.
  • EcoR1 Capital's ten largest holdings make up 74% of its $997M portfolio in Q1 2018.
  • EcoR1 Capital opened 11 new positions and closed 10 in Q1 2018.
  • EcoR1 Capital's portfolio value rose 12% quarter-over-quarter to $997M.

Based on EcoR1 Capital's 13F filing for Q1 2018, filed 15 May 2018.